- Home
- TEVA
as 10-22-2024 4:00pm EST
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
| Founded: | 1901 | Country: | Israel |
| Employees: | N/A | City: | TEL AVIV |
| Market Cap: | 19.7B | IPO Year: | N/A |
| Target Price: | $19.25 | AVG Volume (30 days): | 4.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.07 - $19.08 | Next Earning Date: | 11-06-2024 |
| Revenue: | $16,290,000,000 | Revenue Growth: | 8.48% |
| Revenue Growth (this year): | 4.59% | Revenue Growth (next year): | 4.06% |
Latest Teva Pharmaceutical Industries Limited News
TEVA Breaking Stock News: Dive into TEVA Ticker-Specific Updates for Smart Investing
Insider Monkey
11 hours ago
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
MT Newswires
a day ago
Alvotech, Teva's Stelara Biosimilar Gets FDA Approval for New IV Presentation
GlobeNewswire
a day ago
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Zacks
5 days ago
FOLD Stock Rises on Settling Galafold Patent Dispute With Teva
Zacks
5 days ago
Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar?
MT Newswires
6 days ago
Update: Amicus Therapeutics Shares Surge After Settling Patent Suit Against Teva Pharmaceuticals With License Deal
Benzinga
6 days ago
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
MT Newswires
6 days ago
Amicus Therapeutics Settles Patent Suit Against Teva Pharmaceuticals with License Agreement
Compare TEVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TEVA Teva Pharmaceutical Industries Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.